Biomarin Pharmaceutical Inc (BMRN)
64.26
+0.81
(+1.28%)
USD |
NASDAQ |
Nov 22, 16:00
64.25
-0.01
(-0.02%)
After-Hours: 20:00
Biomarin Pharmaceutical Cash from Investing (Quarterly): -16.16M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -16.16M |
| June 30, 2024 | 90.48M |
| March 31, 2024 | -14.24M |
| December 31, 2023 | -64.96M |
| September 30, 2023 | -45.80M |
| June 30, 2023 | 29.53M |
| March 31, 2023 | -30.01M |
| December 31, 2022 | -54.71M |
| September 30, 2022 | -23.40M |
| June 30, 2022 | -29.70M |
| March 31, 2022 | 87.78M |
| December 31, 2021 | -55.42M |
| September 30, 2021 | -119.85M |
| June 30, 2021 | -120.26M |
| March 31, 2021 | -70.79M |
| December 31, 2020 | 11.03M |
| September 30, 2020 | 106.70M |
| June 30, 2020 | -248.75M |
| March 31, 2020 | 77.40M |
| December 31, 2019 | -48.90M |
| September 30, 2019 | 48.68M |
| June 30, 2019 | 19.67M |
| March 31, 2019 | -50.48M |
| December 31, 2018 | -70.96M |
| September 30, 2018 | 402.33M |
| Date | Value |
|---|---|
| June 30, 2018 | 4.722M |
| March 31, 2018 | -71.73M |
| December 31, 2017 | 139.55M |
| September 30, 2017 | -430.23M |
| June 30, 2017 | -39.82M |
| March 31, 2017 | 25.05M |
| December 31, 2016 | -309.65M |
| September 30, 2016 | -326.94M |
| June 30, 2016 | 75.54M |
| March 31, 2016 | 77.00M |
| December 31, 2015 | 79.55M |
| September 30, 2015 | -63.08M |
| June 30, 2015 | -445.20M |
| March 31, 2015 | -750.87M |
| December 31, 2014 | 462.68M |
| September 30, 2014 | -187.48M |
| June 30, 2014 | -40.36M |
| March 31, 2014 | -38.52M |
| December 31, 2013 | -306.48M |
| September 30, 2013 | 3.313M |
| June 30, 2013 | 12.26M |
| March 31, 2013 | -7.94M |
| December 31, 2012 | -52.35M |
| September 30, 2012 | -20.95M |
| June 30, 2012 | -152.38M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-248.75M
Minimum
Jun 2020
106.70M
Maximum
Sep 2020
-27.00M
Average
-29.86M
Median
Cash from Investing (Quarterly) Benchmarks
| Merck & Co Inc | -3.845B |
| Bristol-Myers Squibb Co | -219.00M |
| Pfizer Inc | -2.057B |
| Biogen Inc | -1.181B |
| Moderna Inc | 721.00M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 221.48M |
| Cash from Financing (Quarterly) | -499.12M |
| Free Cash Flow | 300.88M |
| Free Cash Flow Per Share (Quarterly) | 1.016 |
| Free Cash Flow to Equity (Quarterly) | 694.63M |
| Free Cash Flow to Firm (Quarterly) | 200.30M |
| Free Cash Flow Yield | 2.38% |